Transdermal Delivery of Physostigmine: Effects of Enhancers and Pressure-Sensitive Adhesives

ABSTRACT The purpose of this study was to investigate the effects of various pressure- sensitive adhesives (PSA) on the percutaneous absorption of physostigmine across hairless mouse skin. In addition, the influences of various vehicles and polyvinylpyrrolidone (PVP) on the percutaneous absorption of physostigmine from PSA matrix across hairless mouse skin were evaluated using a flow-through diffusion cell system at 37°C. Physostigmine showed the highest permeability from silicone adhesive matrix, followed by polyisobutylene (PIB), styrene– isoprene–styrene (SIS), acrylic, and styrene–butadiene–styrene (SBS) matrix. Among acrylic adhesives, the permeability of physostigmine was the highest from grafted acrylic adhesive. Polyvinyl pyrrolidone inhibited the crystallization of physostigmine in the PIB adhesive matrix and enhanced the permeability of physostigmine from the PIB adhesive matrix. When esters of sorbitol and fatty acid, polyethylene glycol (PEG) alkyl esters, and caprylic/capric triglycerides were tested, the more lipophilic was a surfactant, the higher the permeation rate within the same group of surfactants. The enhancement effect of PEG derivatives was lower than that of non-PEG derivatives. Among non-linear fatty acid derivatives, linoleate derivatives showed higher permeability of physostigmine than oleate derivatives. This study showed that several non-ionic surfactants, including PEG-20 evening primrose glyceride, enhanced the permeation of physostigmine across hairless mouse skin better than oleic acid.

[1]  Ju-Hyun Kim,et al.  Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. , 2000, International journal of pharmaceutics.

[2]  Hoo-Kyun Choi,et al.  Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix , 1998 .

[3]  C. Chiang,et al.  Control of drug crystallization in transdermal matrix system , 1996 .

[4]  J. Shah Application of kinetic model to in vitro percutaneous permeation of drugs , 1996 .

[5]  Bruno C. Hancock,et al.  Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. , 1995, Journal of pharmaceutical sciences.

[6]  J. Jenner,et al.  Transdermal Delivery of Physostigmine. A Pretreatment Against Organophosphate Poisoning , 1995, The Journal of pharmacy and pharmacology.

[7]  T. Treves,et al.  Transdermal Physostigmine in the Treatment of Alzheimer's Disease , 1994, Alzheimer disease and associated disorders.

[8]  T. Kadar,et al.  Transdermal penetration of physostigmine: Effects of oleic acid enhancer , 1993 .

[9]  S. Cohen,et al.  Kinetics of transdermal penetration of an organic ion pair: physostigmine salicylate. , 1992, Journal of pharmaceutical sciences.

[10]  D. R. Anderson,et al.  Physostigmine (alone and together with adjunct) pretreatment against soman, sarin, tabun and VX intoxication. , 1991, Drug and chemical toxicology.

[11]  Kokubo Takemasa,et al.  Diffusion of drug in acrylic-type pressure-sensitive adhesive matrices. I. Influence of physical property of the matrices on the drug diffusion , 1991 .

[12]  S. Cohen,et al.  Partial molal volumes and solubilities of physostigmine in isopropanol:isopropyl myristate solvents in relation to skin penetrability. , 1991, Journal of pharmaceutical sciences.

[13]  I. Ho,et al.  Trihexyphenidyl enhances physostigmine prophylaxis against soman poisoning in guinea pigs. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[14]  L. Harrell,et al.  The effect of long‐term physostigmine administration in Alzheimer's disease , 1990, Neurology.

[15]  S. Cohen,et al.  Percutaneous absorption of physostigmine: optimization of delivery from a binary solvent by thermodynamic control. , 1990, Journal of pharmaceutical sciences.

[16]  W. H. Carter,et al.  Evaluation of a two-drug combination pretreatment against organophosphorus exposure. , 1990, Toxicology and applied pharmacology.

[17]  Z. Liron,et al.  Penetration of theophylline and adenosine into excised human skin from binary and ternary vehicles: effect of a nonionic surfactant. , 1989, Journal of pharmaceutical sciences.

[18]  R. Mayeux,et al.  Long‐term administration of oral physostigmine in Alzheimer's disease , 1988, Neurology.

[19]  K. A. Walters,et al.  Non‐ionic Surfactant Effects on Hairless Mouse Skin Permeability Characteristics , 1988, The Journal of pharmacy and pharmacology.

[20]  A. Khalique,et al.  Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[21]  P. Hartvig,et al.  Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients , 1986, Acta anaesthesiologica Scandinavica.

[22]  K. A. Walters,et al.  HYDRATION AND SURFACTANT EFFECTS ON METHYL NICOTINATE PENETRATION THROUGH HAIRLESS MOUSE SKIN , 1985 .

[23]  G. Flynn,et al.  Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum * , 1983, The Journal of pharmacy and pharmacology.

[24]  K. Sugibayashi,et al.  Interaction Between Drugs and Pressure-Sensitive Adhesives in Transdermal Therapeutic Systems , 2004, Pharmaceutical Research.

[25]  J. Hadgraft,et al.  Pharmaceutical skin penetration enhancement , 1993 .